Hypericin-functionalized graphene oxide for enhanced mitochondria-targeting and synergistic anticancer effect.

Chao Han,Can Zhang,Ting Ma,Chao Zhang,Jianguang Luo,Xiao Xu,Huijun Zhao,Yan Chen,Lingyi Kong

DOI: https://doi.org/10.1016/j.actbio.2018.07.018

IF: 10.633

2018-01-01

Acta Biomaterialia

Abstract:Effective targeting of mitochondria has emerged as a beneficial strategy in cancer therapy. However, the development of mitochondria-targeting ligands is difficult because of the low permeability of the mitochondrial double membrane. We found that hypericin (HY), a natural product isolated from Hypericum perforatum L., is an effective mitochondria-targeting ligand. HY-functionalized graphene oxide (GO) loaded with doxorubicin (GO-PEG-SS-HY/DOX) increased the synergistic anticancer efficacy of phototherapy and chemotherapy in the absence of apparent adverse side effects. In vitro and in vivo assays suggested GO-PEG-SS-HY/DOX induced the expression of the key proteins of the mitochondria-mediated apoptosis pathway and caused apoptosis of breast carcinoma cells. In addition, GO vehicle exhibited low toxicity toward normal cells, indicating high safety of functionalized GO preparations in antitumor therapy. Therefore, HY-functionalized GO can be successfully used as a platform technology to target mitochondria in cancer cells and improve the therapeutic efficacy of chemotherapeutic drugs.